Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Operating Leases: 2019-2025

Historic Operating Leases for BIO-TECHNE (TECH) over the last 6 years, with Sep 2025 value amounting to $80.7 million.

  • BIO-TECHNE's Operating Leases fell 5.54% to $80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 5.54%. This contributed to the annual value of $84.0 million for FY2025, which is 4.17% down from last year.
  • As of Q3 2025, BIO-TECHNE's Operating Leases stood at $80.7 million, which was down 3.88% from $84.0 million recorded in Q2 2025.
  • Over the past 5 years, BIO-TECHNE's Operating Leases peaked at $97.3 million during Q3 2023, and registered a low of $56.3 million during Q1 2022.
  • Over the past 3 years, BIO-TECHNE's median Operating Leases value was $87.6 million (recorded in 2024), while the average stood at $88.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first declined by 15.67% in 2022, then spiked by 65.52% in 2023.
  • Over the past 5 years, BIO-TECHNE's Operating Leases (Quarterly) stood at $57.7 million in 2021, then spiked by 35.46% to $78.2 million in 2022, then increased by 22.82% to $96.0 million in 2023, then declined by 15.01% to $81.6 million in 2024, then declined by 5.54% to $80.7 million in 2025.
  • Its last three reported values are $80.7 million in Q3 2025, $84.0 million for Q2 2025, and $79.5 million during Q1 2025.